High-dose treosulfan is used in conditioning regimens before hematopoietic stem cell transplantation in children. Pharmacokinetic data to optimize treosulfan dosing are scarce in this patient population. The aims of this study were the development and validation of an analytical method for treosulfan in human serum and the development of a pharmacokinetic model for treosulfan in pediatric patients. Furthermore, we aimed to develop a limited sampling strategy to estimate treosulfan systemic exposure with a minimum of inconvenience and risk for the patient.
AbstrAct
High-dose treosulfan is used in conditioning regimens before hematopoietic stem cell transplantation in children. Pharmacokinetic data to optimize treosulfan dosing are scarce in this patient population. The aims of this study were the development and validation of an analytical method for treosulfan in human serum and the development of a pharmacokinetic model for treosulfan in pediatric patients. Furthermore, we aimed to develop a limited sampling strategy to estimate treosulfan systemic exposure with a minimum of inconvenience and risk for the patient.
A reversed phase high-performance liquid chromatography method using ultraviolet detection to determine treosulfan in human serum samples was developed and validated according to food and drug administration guidelines. Serum pharmacokinetics after the first treosulfan administration was investigated in 20 children using nonlinear mixed-effect modeling, and a limited sampling strategy was developed and validated.
The assay was validated in a 10-500 mg/L concentration range with a lower limit of quantification of 10 mg/L. Accuracies were within the 90%-110% limit. The coefficients of variation of the within-day imprecision and between-days imprecision were less than 5%. Pharmacokinetics was adequately described with a 1-compartment model. The population estimates for clearance (CL) and volume of distribution were 6.85 L/h and 13.2 L for a typical patient of 20 kg, respectively.
Treosulfan exposure could be adequately quantified with 2 samples, at 4 and 7 hours after the start of a 3-hour treosulfan infusion, with a mean deviation of 3% of individual CL and area under the curve based on limited sampling in comparison with the full data set in a total cohort.
In conclusion, in this study a bioanalytical method, PK model, and limited sampling model were developed and validated. Furthermore, PK parameters of 20 pediatric patients were analyzed, demonstrating an interpatient variability in area under the curve of 14.5%. This study demonstrates the essential developments in the optimization of treosulfan therapy based on PK data.
IntroductIon
For a broad spectrum of malignant and non-malignant disorders in pediatric patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option.
However, allo-HSCT is accompanied with considerable acute and long-term toxicity, in which the chemotherapeutic agents given in the conditioning regimen play an important role. [1] [2] [3] Various conditioning regimens have been developed which differ in immunosuppressive and myeloablative potential. Myeloablative conditioning aims at maximum elimination of host hematopoiesis and malignant cells and is therefore associated with a relatively high risk of severe early and late toxicity. Non-myeloablative conditioning and reduced intensity conditioning have been developed to reduce treatment-related toxicities in patients with compromised organ function and for patients in whom full myeloablation is not required for cure of the underlying disease. However, the relapse rates and risk of graft failures in the latter conditioning regimens are higher. 4 Therefore, conditioning regimens could still be improved by combining myeloablative and immunosuppressive capacities with a low toxicity. Treosulfan, a bifunctional alkylating drug, has a suitable profile for use in myeloablative regimens; it gives a rapid and stable myeloablation and exhibits strong immunosuppressive activity to allow donor engraftment. Furthermore, treosulfan seems to have a favorable toxicity profile; diarrhea, mucositis, stomatitis, skin toxicity, and metabolic acidosis (due to the formation of methanesulfonic acid during treosulfan activation) are the most often reported toxicities and treosulfan rarely causes hepatotoxicity. [6] [7] [8] Treosulfan is a structural analogue of busulfan. However, its mechanism of action is different; treosulfanis a prodrug and the mono-and diepoxybutane derivates are responsible for alkylation of DNA and DNA cross-linking. 9 These active derivates are formed by a non-enzymatic intramolecular nucleophilic substitution which is pH and temperature dependent; no conversion of treosulfan occurs at a pH <6.0. 7 Pharmacokinetic data of treosulfan are scarce; studies available in adult patients show a linear relationship between area under the curve (AUC) and dose. 6 Only 2 reports describe the pharmacokinetics of treosulfan in pediatric patients. 10, 11 In these studies, the interpatient variability in exposure AUC of 5 children seems to be very large (CV = 70%), and therapeutic drug monitoring could therefore be of great importance to optimize treosulfan therapy for the individual patient. We developed and validated a reversed phase high performance liquid chromatography (RP-HPLC) method using ultraviolet (UV) detection for quantification of treosulfan inhuman serum. Furthermore, we developed and validated in an independent cohort a population pharmacokinetic model of treosulfan and a limited sampling strategy (LSS). 
MAterIAls And Methods

Patient characteristics
bioanalytical method development
The bioanaltyical method for treosulfan presented in this article is based on the method to determine busulfan developed in our department 12 and the method for treosulfan presented by Glowka et al. 11 and Hilger et al. 13 Because treosulfan is non-enzymatically converted into its active metabolites, it is suggested that the concentration of treosulfan itself is a good representation of the alkylating activity.
chromatographic conditions
An RP-HPLC method using UV detection to determine treosulfan in human serum samples was Treosulfan and busulfan are derivatized separately; busulfan is added at the end of the treosulfan derivatization. In this way, complete derivatization of both compounds can be achieved.
When busulfan is derivatized at the same conditions as treosulfan, the busulfan derivate is partly degraded, causing disturbance of the chromatograms. Two milliliters of ethyl acetate was added, vortexed for 30 seconds, and after centrifugation at 3220 g during 3 minutes, the organic layer was transferred into a new glass tube and evaporated to dryness at 50°C under nitrogen gas. The residue was dissolved in 300 mL of methanol of which 200 mL was transferred into a glass autoinjector vial.
Validation
The analytical assay was validated according to food and drug administration guidelines.
14 Serum QC samples were prepared with a concentration of 15, 80, and 400 mg/L. Accuracy, within-day imprecision and between-day imprecision were determined by analyzing each QC sample 5 times on 1 day and on 5 different days. Accuracy was defined as the mean measured concentration and should be between 90% and 110% of the nominal concentration. The imprecision was expressed as % CV and should be less than 10% for within-day imprecision and less than 15% for between-day imprecision. The lower limit of quantification was calculated from the residual standard deviation (using 99.9% confidence interval) and the slope of the calibration line. The recovery of treosulfan extraction was determined in triplicate by comparing processed serum samples of 15, 80, and 400 mg/L with reference samples in citrate buffer (pH 5.5) of the same concentration. Selectivity and matrix interference was investigated by measuring 2 different concentrations prepared in 6 different blank serum samples. When CV was less than 10%, the interferences of the matrix were considered insignificant. Short-term and long-term stability at 2 concentrations (20 and 400 mg/L) were studied at room temperature and 4°C (short term) and at -20°C and -80°C (long term). Furthermore, postprocessing stability and freeze-thaw stability were also studied at the same 2 concentrations. All stability measurements were performed in triplicate. When concentrations measured are within 100% ± 10% of the initial concentration, the samples were considered stable.
Pharmacokinetics
Blood sampling
All patients received 14 g/m 2 treosulfan in a 3-hour infusion on 3 consecutive days. On day 1, patient blood samples were collected at 1.5, 3.5, 4, 5, 7, and 9 hours after the start of a 3-hour treosulfan infusion. Blood samples were collected in serum tubes without gel through the lumen of the catheter that was not used for intravenous treosulfan administration. Samples were centrifuged as quickly as possible after the collection of the patient sample, at least within 5
hours. Serum was transferred into a polystyrene tube and stored directly at -80°C until analysis.
Pharmacokinetic model development
The treosulfan population pharmacokinetic model was developed by using nonlinear mixedeffect modeling as implemented in the NONMEM software package (version 7 level 2; Icon Development Solutions, Ellicott City, MD). Diagnostic graphics, exploratory analyses, and postprocessing of NONMEM output were performed using S-Plus (version 8.0 Professional; Insightful Corp, Seattle, WA). In the first step, the PK model was developed using the data from an initial cohort of 12 patients. The final PK model was validated using the data from a second independent cohort of 8 patients. Different linear compartmental models (1-, 2-, or 3-compartmental models)
were explored to describe the PK of treosulfan. The parameters (clearance (CL) and volume of distribution (V)) among individuals were assumed to be log-normally distributed. Consequently, the random effects at the individual level were implemented as exponential terms (Equation 1): 
where C ij is the j th observation for the i th individual; C pred,ij is the corresponding model predicted value and ε ij represents the residual deviation of the observed concentration from the predicted concentration. ε ij is assumed to follow a normal distribution with mean zero and variance σ
Improvement in the fit of the model was assessed using the likelihood ratio test. This statistical test compares the fit of 2 models by evaluating the difference in the minimum value of objective function (MVOF), which is equal to minus twice the log-likelihood of the data. 15 A difference of 10.8 points in MVOF was considered statistically significant (p < 0.001, given 1 degree of freedom, assuming χ 2 distribution). In addition, standard goodness-of-fit plots were inspected visually to evaluate the model fit and the predictive performance of the developed model was evaluated using simulation-based diagnostics such as visual predictive check (VPC). In the VPC, it was investigated visually if the identified model predicts the median concentration and variability from the population that was used for model identification adequately. To this end, the PK of each individual was simulated 500 times by means of a Monte Carlo simulation. The distribution (median and 10 th and 90 th percentiles) of the simulated concentration-time profiles was compared with the distribution of the observed concentration-time profiles.
Limited sampling strategy
The aim of developing a LSS was to make adequate estimates of treosulfan exposure AUC with a minimal number of serum samples and thus with a minimal patient burden. A hundred data sets were simulated using the final population PK model. These 100 data sets were back fitted with the final model, resulting in 100 population estimates of CL and V. Different strategies of 
External validation
The external validation of the population PK model to describe the concentration-time profiles of treosulfan was performed using a second independent cohort of 8 patients. 
results description of the patient populations
The population PK model for treosulfan was developed using a first cohort of 12 pediatric patients. Details on the patient characteristics, conditioning regimens, diagnosis for HSCT, and donor information are presented in Table 6 .1 for the first and second cohort separately and the total of 20 patients. Briefly, the mean age and weight of the patients in this first cohort were 6.9
(± 5.5) years and 21.5 (± 14.2) kg, respectively, and 7 patients were male. In the second cohort, the mean age was 5.4 (± 5.5) years and the mean weight was 21.0 (± 14.3) kg and 6 patients were male. When looking at the combination of both cohorts, for 4 patients, the indication for HSCT was a hematologic malignancy: 3 patients were diagnosed with secondary (n = 1) or relapsed (n = 2) acute myelogenous leukemia and 1 patient with juvenile myelomonocytic leukemia.
Twelve patients had a hemoglobinopathy; 11 patients with a homozygous β-thalassemia and 1 patient with sickle cell disease. Three patients had a (severe) combined immunodeficiency and 
Validation of the treosulfan assay
A calibration range of 10-500 mg/L treosulfan in serum was selected. Average lower limit of quantification over 8 calibration lines was 10 mg/L, which is lower than the lowest calibrator.
Chromatograms of blank, QC low, and a patient serum sample are shown in Supplemental Accuracy of the samples with a concentration of 100% and 150% of the highest calibrator was 100.3% and 95.5%. Accuracies for each of the 3 QC samples were within the 90%-110% limit.
The coefficient of variation of the within-day imprecision and between-day imprecision was less than 5% (Table 6 .2). The selectivity of the assay was appropriate, resulting in a CV of less than 5% when measuring treosulfan in 6 different blank samples at the lower limit of quantification level (10 mg/L). Furthermore, in the chromatogram of a patient, no interference due to comedication was observed (see Supplemental Figure 6 .1). This is due to the selectivity of the derivatization of treosulfan and busulfan. No carryover was observed after the analytical run of a sample with a concentration of 400 mg/L. The recoveries of treosulfan were appropriate for all 3 QC levels showing recovery rates of 95%, 96%, and 84% at 15, 80, and 400 mg/L, respectively. An overview of stability data is shown Supplemental at -20°C for treosulfan determination. Additionally, treosulfan serum samples are stable after 3 freeze and thaw cycles at -80°C and during 5 hours postprocessing.
Pharmacokinetic model
The time course of the plasma concentration of treosulfan was adequately described using Table 6 .3a.
limited sampling strategy
Predictive performance (MPE and MAPE) of the different limited sampling strategies is listed in Table 6 .4. Two samples were sufficient to estimate the CL and V at the population level. Two time points at 4 and 7 hours are preferred from a practical perspective (no sampling during infusion). Samples taken between 4-5 hours and 6-7 hours after the start of a 3-hour infusion will give a good estimation of treosulfan exposure.
external validation
The model, developed using the data from the first cohort, was fitted to the data of a second the difference in AUC was above 10% (e.g. 14%). This patient was a relatively older child of 16 years weighing 52 kg. The difference in AUC is probably attributable to the small data sets for model development and validation; especially the number of older patients was limited. The parameter estimates were updated by fitting the final model to the data from 2 cohorts (n total = 20) (Table 6 .3b). In addition, the LSS was assessed using the updated model parameters based on the combined data set of 20 patients. As a result, with only 2 samples of each individual, a good estimate of individual CL and AUC was obtained. A mean deviation of 3% in individual CL and AUC was observed when comparing the reduced with the full data set (66 samples), with 
dIscussIon
We successfully developed and validated a bioanalytical method to quantify treosulfan concentrations in serum and a pharmacokinetic model to describe the concentration-time profile for treosulfan in pediatric patients. Furthermore, an LSS was developed to estimate treosulfan exposure, expressed as AUC, in pediatric patients based on only 2 serum samples.
This bioanalytical method combined with a PK model is crucial to study whether outcome after conditioning with treosulfan is related to exposure and if treosulfan conditioning regimens can be optimized by targeting exposure. Furthermore, the limited sampling model is essential in studying treosulfan PK in pediatric patients, especially the youngest.
Two analytical methods for analyzing treosulfan have been described previously. Glowka et al. 11 presented methods for analyzing treosulfan in biologic fluids based on RP-HPLC with refractometric detection. Another article of Glowka et al. 16 describes a HPLC method using UV detection at 264 nm. Treosulfan and its metabolites were made detectable by derivatization minutes. UV detection is also used in the method described in this article because this is a more selective and sensitive detection method compared with refractometric detection. In addition, UV detection is more commonly available and therefore the method presented in this article is easier to implement in most laboratories. However, treosulfan and busulfan (IS) detection with UV is possible only after derivatization of the compounds, resulting in more extensive sample preparation. Our analytical method is less time consuming due to an optimized derivatization process using DDTC, resulting in derivatization of treosulfan at 50°C during only 15 minutes, and an analytical runtime of 15 minutes.
Treosulfan itself is a prodrug, non-enzymatically, and pH dependent converted into its active metabolites. In one of the analytical methods of Glowka et al. 16 also, the active metabolites were analyzed. However, in this study, diepoxide was not detected in patient samples because of fast elimination. Furthermore, it is assumed that the concentration of treosulfan itself is a good representation of the alkylatingactivity. 13 The precise role of treosulfan or its metabolites in effectiveness of the conditioning is yet unclear.
In both methods presented by Glowka et al., patient blood samples were pretreated immediately after collection with citric acid to stop degradation of treosulfan, which in the clinic can be a problematic logistic step. Therefore, we thoroughly studied the stability of treosulfan in different biologic fluids under various conditions. These experiments indicated stability of treosulfan in whole blood and serum after collecting the samples during 5 hours, resulting in a more feasible methodology for patient sample collection.
The development of the pharmacokinetic model is based on the data from 12 patients. Despite the relative low number of subjects, multiple sampling in these subjects (approximately 6 samples per patient) facilitated the development of a PK model that adequately describes the concentration-time profiles of treosulfan and the observed variability. It was observed that combining the first and second cohorts resulted in different population parameter estimates.
By increasing the number of patients in the analysis, the level of confidence in the developed PK model and population parameters increases and it is therefore recommended to update model parameters in future after including the data of new (pediatric) patients. In the development of a limited sampling model, different strategies were tested on a population level. The strategy with sampling at 4 and 7 hours after the start of the infusion was chosen, although MPE and MAPE values of the t = 1.5 and 5 hours strategy were slightly better. The first strategy was chosen because of the practical reason of no sampling during treosulfan infusion. Furthermore, the predictive performance was assessed on a population level. When considering the individualized values of CL and AUC in the total cohort, it is demonstrated that our LSS adequately predicts treosulfan CL and AUC based on the 2 samples at 4 and 7 hours. This resulted in a total cohort of 20 patients a mean deviation of 3% in individual CL and AUC when comparing the limited sampling set with the full data set.
In our study, 6 blood samples of 1-2 mL on 1 day were collected. Therefore, one of the exclusion criteria was bodyweight under 10 kg. Because of this criterion, the treosulfan exposure and PK of patients under 10 kg body weight could not be studied. The LSS reduces the burden of sampling significantly and may allow investigating the PK of children with lower body weights in the future.
To date, pharmacokinetic data of treosulfan are scarce. In adult patients, treosulfan shows predictable linear pharmacokinetics. 6 For pediatric patients, only 1 study is published presenting PK data in a reasonable number of pediatric patients. 10 In this study of Glowka et al., 7 patients were analyzed, receiving different doses of treosulfan (10, 12, or 14 g/m 2 ), the exposure levels found were in accordance with the levels of the 20 patients in our study. The variability in exposure of 5 patients receiving the same dose was very large (CV = 70%). The cause of this large variability is unknown; however, it is based on a very small number of patients. In our study, the interpatient variability in exposure was found much smaller, 14%. This difference in variability could be due to the number of patients, Glowka et al. studied only 5 patients with the same dose. Alternatively, the trapezoidal rule was applied for AUC calculation of the individual patients, which could lead to less precise determination of the AUC.
Treosulfan is an attractive candidate for use in conditioning regimens before HSCT and is more often used in pediatric patients due to its rapid and stable immunosuppressive activity and favorable toxicity profile. In the study, a bioanalytical method, population PK model, and LSS for treosulfan were developed and validated. In the future, more data need to be collected to study the relationship between outcome and treosulfan exposure, especially in the youngest children with an age under 2 years.
